Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
psilocybin + MDMA
- Development stage
- Unknown
- Lead developer
- Johns Hopkins University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Psilocybin + MDMA is an investigational drug combination being studied by the Johns Hopkins Center for Psychedelic and Consciousness Research for the treatment of post-traumatic stress disorder (PTSD), particularly in military veterans. This combination therapy, often associated with the PAMVET (Psilocybin and MDMA for PTSD in Veterans) trial, involves the co-administration of psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) alongside structured psychotherapy. Psilocybin acts as a partial agonist at the serotonin 5-HT2A receptor, inducing introspective and mystical-type experiences, while MDMA acts as a monoamine releasing agent and reuptake inhibitor, promoting prosocial effects and fear extinction. The rationale for the combination is to leverage the synergistic therapeutic potential of both compounds to facilitate the processing of traumatic memories in a controlled clinical setting.
- Other names
- Psilocybin and MDMAMDMA and psilocybinPAMVET
02
Targets
HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)HTR2C (5-hydroxytryptamine 2C receptor)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on psilocybin + MDMA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on psilocybin + MDMA.